Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 18/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532766 | 0.86 | OPRK1 (0.41) | RAF1BRAFOPRK1OPRM1OPRD1 | |
| SCHEMBL2531291 | 0.86 | RAF1 (0.32) | RAF1BRAFCHEK1ATRPDCD1 | |
| SCHEMBL2533384 | 0.85 | RAF1 (0.34) | RAF1BRAFOPRK1OPRM1OPRD1 | |
| SCHEMBL12220416 | 0.85 | RAF1 (0.34) | RAF1BRAFOPRK1OPRM1OPRD1 | |
| SCHEMBL1725307 | 0.85 | RAF1 (0.34) | RAF1BRAFOPRK1OPRM1OPRD1 | |
| SCHEMBL1711441 | 0.85 | HTT (0.45) | OPRK1OPRM1OPRD1 | |
| SCHEMBL2533803 | 0.83 | OPRK1 (0.38) | RAF1BRAFOPRK1OPRM1OPRD1 | |
| SCHEMBL12220414 | 0.79 | PIK3CA (0.41) | RAF1BRAFOPRK1OPRM1 | |
| SCHEMBL2533307 | 0.78 | ALDH1A1 (0.35) | RAF1BRAFCHEK1ATRPDCD1 | |
| SCHEMBL2527338 | 0.72 | RAF1 (0.33) | RAF1BRAFCHEK1ATRPDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| EP-2344490-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES ACTIVE ON PI3K | Merck Serono S.A. (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010037765-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CG | RAF1 141/4885BRAF 41/4885OPRK1 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.